Efficiency of Comprehensive Chromosomal Testing of Trophectoderm Biopsies of Blastocysts in In Vitro Fertilization

Last updated: January 18, 2024
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Infertility

Treatment

Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)

Clinical Study ID

NCT04758819
APHP 200006
  • Ages 35-41
  • All Genders

Study Summary

Preimplantation embryo aneuploidy is a major source of adverse outcomes in human reproduction since it leads to implantation failure, early pregnancy loss or severe chromosomal diseases. The risk of embryos aneuploidy is drastically increased after 35 years old. The intra uterine transfer of euploid embryos assessed through such techniques as next-generation sequencing (NGS) based Comprehensive chromosomal Testing of Trophectoderm (TE) biopsies of Blastocysts (CTTEB), may improve implantation and live birth rates, and decrease miscarriage rates. But no randomized controlled trial (RCT) was ever performed to test the interest of CTTEB for women that really needed it (≥35 to ≤ 41 years old). In this multicentre randomized-controlled-trial, the investigators will compare live birth rate obtained after the first single frozen-thawed blastocyst transfer cycle following the freeze-all-Intracytoplasmic sperm injection cycle in infertile and old couples between two different strategies of Day 5/6 blastocyst selection:

  • Control group: morphological criteria (Istanbul consensus)

  • Interventional group: international recommendations after CTTEB (www.pgdis.org; Newsletter May 27, 2019).

Eligibility Criteria

Inclusion

Inclusion Criteria Women :

  • Age ≥35 to ≤ 41 years old (according to date of birth at time of informed consent) whoare eligible for ovarian stimulation and ART treatment, including intracytoplasmicsperm injection (ICSI)
  • BMI=18-35 kg/m2 inclusive
  • No intrauterine and/or endometrial abnormalities that would interfere withimplantation or pregnancy (for instance polyp, fibroid, …) Inclusion Criteria Men:
  • Use of ejaculated motile sperm (donated and/or cryopreserved sperm is allowed)
  • Age ≤ 50 years old Inclusion Criteria Couples:
  • Primary or secondary infertility
  • Dated and signed inform consent
  • Affiliated to National Insurance
  • French speaking, able to understand the study Criteria after randomization Couple having at least one blastocyst with morphological score on Day 5/6 of in vitroembryo development (blastocoel expansion ≥3 and inner cell mass graded A, B or C andtrophectoderm graded A or B

Exclusion

Exclusion Criteria: Women:

  • Recurrent implantation failure (previous transfer of least 5 good grade blastocysts inat least 3 fresh or frozen cycles)

  • Personal history of recurrent miscarriages (more than two miscarriages)

  • Altered ovarian reserve: Identified risk of poor ovarian response (history of oocytepuncture with less than 3 oocytes) or AMH<1.1 ng/mL and AFC<5)

  • Presence of non isolated uni- or bilateral hydrosalpinx

  • History or presence of ovarian, uterine or mammary cancer

  • Contraindication to being pregnant and/or carrying a pregnancy to term

  • Women with uterine polyps diagnosed during COS

  • Known allergy or hypersensitivity to human gonadotropin preparations or to compoundsthat are structurally similar to any of the other medications administered during thetrial

  • Substance abuse that would interfere with trial conduct, as determined by theinvestigator

  • Pregnant patient, nursing patient Men:

  • Use of testicular or epididymal sperm Couples:

  • Known infection with human immunodeficiency virus, active hepatitis B or C virus inthe female or male partner

  • Scheduled for an embryo transfer on day 2 or 3

  • Embryo freezing refusal

  • Scheduled for a fresh embryo transfer

  • Scheduled with an egg donation

  • Scheduled with autologous oocytes thawing

  • Scheduled for a preimplantation genetic diagnosis

  • Participation in another ART clinical trial within the past 30 days

  • Participation with another interventional study involving human subjects Exlusion criteria to check on randomization day :

  • Women with less than 3 follicles ≥ 14 mm on the triggering day or the day before thetriggering

Study Design

Total Participants: 700
Treatment Group(s): 1
Primary Treatment: Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)
Phase:
Study Start date:
July 12, 2021
Estimated Completion Date:
January 31, 2026

Study Description

The presence of chromosomal abnormalities (aneuploidy) in the pre-implantation embryonic stage is one of the major causes of human reproductive disorders, as it is responsible for embryo implantation failures, early or late miscarriages and the birth of children with chromosomal syndromes. This is mainly due to the existence of chromosomal abnormalities of meiotic, especially maternal, or mitotic origin occurring during the first three cell divisions of the embryo. As a result, human embryos have higher rates of aneuploidy than other species. Thus, it has been suggested that only 30% of conceptions reach term.

The objective of Assisted Reproductive Technologies (ART) is to optimize the chances of conception and delivery of healthy new-borns. It is necessary to improve the results of IVF (in vitro fertilization) programs and to reduce adverse effects (miscarriages, multiple pregnancies), especially in couples with patients with poor prognosis, such as older women. The choice of embryos to be transferred is a key step for the success of ART infertility treatments.

Currently, the choice of embryos is based solely on their morphology, evaluated on the 5th or 6th day of development at a stage known as the "blastocyst". Each embryo is observed under the microscope and described according to standardized morphological criteria. This description of the blastocyst is based on 3 constituents of the embryo: the degree of expansion of the blastocoelic cavity, the appearance of the internal cell mass (ICM) and the presence of trophectodermal cells (TE). These criteria have been described as predictive of live birth rates after transfer of fresh or thawed embryos. However, its ability to identify the embryo with the highest potential for implantation is debatable, due to its weak association with embryonic chromosomal status, which is a critical factor in the implant potential of each embryo. In addition, it is known that embryos that do not meet these morphological criteria are discarded, although it has been proven that their transfer could lead to a live birth.

Since the risk of embryonic aneuploidy is significantly increased after the age of 35, the objective of our RCT is to evaluate the efficacy of the CTTEB using the latest technologies and methodologies (i.e., combined embryo culture to blastocyst stage, immediate freezing of the embryonic cohort with delayed transfer, TE biopsy, NGS, and Single Embryo Transfer (SET)) in the management of infertile patients over 35 years of age. The live birth rate obtained after the first transfer of a single frozen embryo will be compared between two groups of couples, randomized in two arms: i) transfer of a single euploid blastocyst; ii) transfer of a single blastocyst of unknown chromosomal status, chosen on the basis of the usual morphological criteria, in the first thawing cycle following the freezing of all the blastocysts of the patient couples.

In addition, the culture medium of each embryo collected will be analysed in a second stage to assess whether it is possible to develop a diagnosis of aneuploidy without the need for trophectoderm biopsy (non invasive).

Connect with a study center

  • Hôpital Jean Verdier

    Bondy, 93
    France

    Active - Recruiting

  • Hôpital Antoine Béclère

    Clamart, 92140
    France

    Active - Recruiting

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63000
    France

    Active - Recruiting

  • CHU Dijon

    Dijon, 21079
    France

    Active - Recruiting

  • Hôpital Arnaud de Villeneuve

    Montpellier, 34295
    France

    Active - Recruiting

  • CHU Nantes

    Nantes, 44093
    France

    Active - Recruiting

  • Hopital Tenon

    Paris, 75020
    France

    Site Not Available

  • Hôpital Cochin

    Paris, 75014
    France

    Active - Recruiting

  • CHU Strasbourg

    Schiltigheim, 67300
    France

    Active - Recruiting

  • Hôpital Foch

    Suresnes, 92
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.